UOC
FOLD

UBS O'Connor’s Amicus Therapeutics FOLD Stock Holding History

UBS O'Connor’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-100,000
Closed -$5K – 435
2016
Q4 		$5K Buy
+100,000
New +$692K ﹤0.01% 393

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS O'Connor's FOLD Position: Q4 2025 in Review

UBS O'Connor opened a new position in Amicus Therapeutics (FOLD) in Q4 2025: 1,000,000 shares worth $14.2M. The stake represents 0.42% of the portfolio and ranks #25 among its holdings. This is a return to the name: UBS O'Connor previously reported a position in FOLD as recently as Q2 2016.

UBS O'Connor first reported a position in FOLD in Q4 2014 and has held it in 6 quarters since. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

  • UBS O'Connor held 1,000,000 shares of Amicus Therapeutics worth $14.2M as of Q4 2025.
  • Amicus Therapeutics was a new UBS O'Connor position in Q4 2025.
  • Amicus Therapeutics made up 0.42% of UBS O'Connor's portfolio in Q4 2025, its #25 holding.
  • UBS O'Connor first reported a position in Amicus Therapeutics in Q4 2014 and has held it in 6 quarters since.
  • 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on UBS O'Connor's 13F filing for Q4 2025, filed 13 Feb 2026.